AzTrials
AzTrials

InfertilityAMHNCT02013973

Predictive Value of AMH in IVF; a Prospective RCT

A study testing AMH-analysis in people with Infertility, run by Ann Thurin Kjellberg at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary aim of this trial is to compare two groups of women undergoing IVF (IVF=in vitro fertilisation ) treatment, to investigate if assessment of AMH (AMH=Anti-Müllerian hormone ), in addition to assessment of maternal age, AFC (AFC=antral follicle count ) and BMI (BMI=body mass index ) gives a more optimal COH… Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Infertility
What is being tested?
AMH-analysis
Could I receive a placebo?
No, everyone receives an active treatment
How many people
308 participants
Where
1 siteSweden
Study dates
Mar 2013to Sep 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Indication for IVF with standard method for the couple exists (i.e. more than one year of infertility and work-up has been performed suggesting IVF as the proper treatment and no known severe male factor exists).
  • Age >18 and < 40 years.
  • BMI > 18 and < 35.
  • First IVF treatment for the woman.
  • Willing to participate in randomization between intervention group and control group and to sign informed consent.
  • -

Who cannot join

  • IVF with ICSI (ICSI=intracytoplasmic sperm injection ) planned.
  • Oocyte donation planned.
  • Treatment with PGD (PGD=preimplantation genetic diagnosis ) planned.
  • Medical or psychological condition indicating ineligibility for the study.
  • Patient with insufficient knowledge of Swedish language to understand patient information.
  • Previous participation in this study.
  • -

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Sahlgrenska University Hospital, Reproductive medicine,

    Gothenburg, SE-41345

Other trials in Sweden

About this study

Official title: Predictive Value of AMH (AMH=Anti Müllerian Hormone ) in IVF (IVF=In Vitro Fertilization ); a Prospective Randomized Controlled Trial

The primary aim of this trial is to compare two groups of women undergoing IVF (IVF=in vitro fertilisation ) treatment, to investigate if assessment of AMH (AMH=Anti-Müllerian hormone ), in addition to assessment of maternal age, AFC (AFC=antral follicle count ) and BMI (BMI=body mass index ) gives a more optimal COH (COH=controlled ovarian stimulation than does assessment of only age, AFC and BMI, measured as number of patients obtaining 5-12 oocytes during COH.

Read the detailed description

At the first visit to the IVF-clinic a CRF (CRF=Case Report Form) of demographics will be filled in regarding age, BMI, parity, presence of PCOS (PCOS=polycystic ovarian syndrome ), smoking and duration of infertility and a blood sample for serum-AMH is taken and frozen for later analysis. The serum-AMH level is constant during the menstrual period (La Marca et al 2006) and a blood sample can be taken on any cycle day. The AMH assay used is the Beckman Coulter AMH Gene II assay. Classification of the serum AMH values into expected low-, normal-, or high ovarian response is based on the data presented a large prospective cohort study of patients going through COH (Nelson et al 2009). Since that publication used an older assay the reference intervals are calculated and translated as described in a recent publication on AMH assays (Nelson et al 2012). Serum-AMH level increases during GnRH (GnRH= gonadotropin releasing hormone) agonist downregulation (Jayaprakasan et al 2008), thus the blood sample is preferably taken before start of down-regulation. A long GnRH agonist treatment protocol is used. Patients are down-regulated with GnRH agonist from luteal phase, or first cycle day when anovulatory patient, until estradiol is < 200 pmol/l. After down-regulation, an assessment of AFC will be performed by sonography, and the patient will be randomized.

For the patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and serum-AMH. For the patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC. The AMH blood sample in this group will be analyzed after completion of the study.

Stimulation is started with a dose of rFSH (rFSH=recombinat follicle stimulating hormone) calculated according to the dose algorithms used in the two groups. The name of the gonadotropin preparation, the dose and number of treatment days will be recorded. The same applies for all drugs used. Monitoring will be performed with mandatory estradiol on the day of stimulation start and on stimulation day 6. The dose of gonodotropin can be adjusted on day 7. If estradiol is > 1200 pmol/l the dose is reduced with one step according to the dose algorithm. If estradiol is < 350 pmol/l the dose is increased with one step according to the dose algorithm. Vaginal sonography is performed on stimulation day 9-11 to estimate the number and size of follicles. The number of follicles >10 mm at sonography 0-2 days before ovulation induction is recorded. Ovulation induction with 6500 IU (IU=international units) rHCG (rHCG=recombinant human chorion gonadotropin ) is given when >=2 follicles >=17 mm. 36 hours after ovulation induction transvaginal oocyte pickup is performed according to standard procedure at the clinic using sedation and paracervical administration of local anaesthetics, and all follicles > 10 mm are punctured. The oocytes will be fertilized using standard IVF procedure. In the case of an unexpected poor semen sample on the day of ovum pick-up microinjection will be performed. The fertilization rate is recorded. Embryo transfer is done on day 2 or 3 according to routine procedures in the clinic. In the case of no GQE (GQE=good quality embryos ) it is allowed to perform double embryo transfer, otherwise single embryo transfer is mandatory. Luteal phase support using vaginal route is given from the day of embryo transfer and for 14 more days, until pregnancy test (urinary ). In case of impending OHSS (OHSS=ovarian hyperstimulation syndrome ), where decision is made to cryopreserve all embryos, the outcome of the first transfer of a cryopreserved embryo will be included in the study results for secondary endpoints. In case of pregnancy, an early vaginal sonography is performed in pregnancy week 7-8. The number of cancelled cycles due to poor response is recorded. The number of patients having moderate or severe OHSS, requiring intervention, will be recorded until four weeks after ovum pick up.

Conditions
Infertility
Being tested
AMH-analysis
Keywords
Anti mullerian hormone, In vitro fertilization, Optimal treatment, Randomized controlled trial
Medical subject headings
Infertility

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AMH-analysisOther

    At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.

Study groups in NCT02013973
Study groupRoleWhat they receive
AMH-groupExperimentalThe patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
Receives: Other: AMH-analysis
Non-AMH-groupNo interventionThe patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of patients obtaining 5-12 oocytes during COH

    Measured: 2 years

Secondary outcomes (5)
  1. Cancelled cycle rate

    Measured: 2 years

  2. Total dose of gonadotropins

    Measured: 2 years

  3. Number of participants developing moderate or severe OHSS

    Follow-up of OHSS rate performed 4 weeks after ovum pick up

    Measured: 2 years

  4. Embryology

    Number of oocytes retrieved, fertilization rate, number of good quality embryos, number of surplus embryos possible to cryopreserve, number of embryos transferred

    Measured: 2 years

  5. Pregnancy and live birth rate

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2013 (estimated)
  2. Study startMar 2013
  3. Primary completionMay 2016
  4. Study completionSep 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
308 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02013973
Sponsor's protocol ID
AMH Sahlgrenska
Acronym
AMH
Status last verified
Dec 2016
First submitted
6 Dec 2013
Last updated
13 Dec 2016
Results posted
No
Data monitoring committee
No

Publications

  • Magnusson A, Olerod G, Thurin-Kjellberg A, Bergh C. The correlation between AMH assays differs depending on actual AMH levels. Hum Reprod Open. 2017 Dec 8;2017(4):hox026. doi: 10.1093/hropen/hox026. eCollection 2017.

    PubMed 30895238

Questions about this trial

What is this clinical trial studying?

A study testing AMH-analysis in people with Infertility, run by Ann Thurin Kjellberg at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of patients obtaining 5-12 oocytes during COH (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02013973, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in